European policies on orphan diseases and drugs stimulate drug development, but could be improved

Author：

ISSN： 1172-0360

Source： Drugs & Therapy Perspectives, Vol.27, Iss.5, 2011-05, pp. : 24-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chorismate Synthase: An Attractive Target For Drug Development Against Orphan Diseases

Current Drug Targets, Vol. 8, Iss. 3, 2007-03 ,pp. : 437-444

Bentham Science Publishers

Access to resources Recommend Favorite

Spending on orphan drugs: European perspective

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 614, 2010-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Editorial [ Hot Topic: Targets for Development of Drugs Against Orphan Diseases (Guest Editor: Walter Filgueira de Azevedo Jr.) ]

Current Drug Targets, Vol. 8, Iss. 3, 2007-01 ,pp. : 387-387

Bentham Science Publishers

Access to resources Recommend Favorite

Predictors of orphan drug approval in the European Union

By Heemstra Harald

European Journal of Clinical Pharmacology, Vol. 64, Iss. 5, 2008-05 ,pp. : 545-552

Springer Publishing Company

Access to resources Recommend Favorite

Orphan Nuclear Receptors as Targets for Drug Development

By Mukherjee Subhajit Mani Sridhar

Pharmaceutical Research, Vol. 27, Iss. 8, 2010-08 ,pp. : 1439-1468

Springer Publishing Company

Access to resources Recommend Favorite